Lamivudine NDC 50742-623

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-623Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0623Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-623-60	50742062360	60 TABLET in 1 BOTTLE, PLASTIC (50742-623-60)Marketed from Feb 1, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206974
Marketing start: Feb 1, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Analog (EXT)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 50742-623_723a8db6-baa2-47f7-a352-0ed4c25a184eSPL ID 723a8db6-baa2-47f7-a352-0ed4c25a184eSPL set ID 47f8be59-178c-4bad-96a4-a5c82784f308RxCUI 199147, 349491UNII 2T8Q726O95UPC 0350742623600
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742062360 followed by a unit qualifier and the quantity

Package 50742-0623-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 24, 2018. This label includes a boxed warning.

Indications (excerpt from the label)

LAMIVUDINE is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. LAMIVUDINE is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Limitation of Use: The dosage of this product is for HIV-1 and not for HBV. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206974

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206974
Product	Strength	Form · route	Labeler	Product NDC
Lamivudine	Lamivudine 300 mg/1	TabletOral	Ingenus Pharmaceuticals, LLC	50742-624